Endocrinology and Metabolism

Luca Giovanella (Giovanella L)

3 Articles

Thyroid
^99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities: Luca Giovanella, Gaetano Paone, Teresa Ruberto, Luca Ceriani, Pierpaolo Trimboli; Endocrinol Metab. 2019;34(1):63-69. Published online February 15, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.1.63

4,283 View
66 Download
6 Web of Science
5 Crossref

Background

Postoperative routine radioiodine (RAI) treatment is currently debated for patients with low-risk differentiated thyroid carcinoma (DTC) patients. If performed, a low ¹³¹I activity (i.e., 1 to 2 GBq) is recommended with the aim to ablate thyroid remnant and facilitate subsequent follow-up by thyroglobulin measurement. The purpose of this study was to evaluate the relationship between postsurgical technetium-99m (^99mTc)-pertechnetate scintigraphy and the rate of successful remnant ablation after low activity radioiodine ablation in patients with DTC.

Methods

Enrolled were 193 patients with low risk DTC who underwent total thyroidectomy and RAI ablation with a fixed 1.1 GBq activity of ¹³¹I. ^99mTc-pertechnetate scans were done and thyrotropin stimulated thyroglobulin (sTg) levels measured just before ablation. Ablation effectiveness was assessed 6 to 12 months later by sTg measurement, neck ultrasound and diagnostic whole body scan.

Results

A negative ^99mTc-perthecnetate scans was the best predictor of successful ablation (P<0.001) followed by preablative sTg levels <0.8 ng/mL (P=0.008) and ^99mTc-pertechnetate uptake rate values <0.9% (P=0.065). Neither sex nor age of the patient at the time of ablation or tumor histology and size showed a significant association with the rate of successful ablation.

Conclusion

The ^99mTc-pertechnetate scintigraphy is a simple and feasible tool to predict effectiveness of low activity ¹³¹I thyroid to ablate thyroid remnants in patients with DTC.

Citations

Citations to this article as recorded by

Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients
Maythinee Chantadisai, Jirarot Wongwijitsook, Napat Ritlumlert, Yothin Rakvongthai
Scientific Reports.2024;[Epub] CrossRef
The prognostic value of post thyroidectomy Tc-99m pertechnetate thyroid scan in patients with differentiated thyroid cancer
L.M. Eloteify, Samy M. Algizawy, Aya K.M. Abdelnaim, Nesreen Mekkawy
Nuclear Medicine Communications.2023; 44(1): 38. CrossRef
Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer
Qian Zhang, Weina Xu
Nuclear Medicine Communications.2022; 43(10): 1051. CrossRef
Clinical significance of extra-thyroid 99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma
Bin Long, Li-Fang Yao, Shou-Cong Chen, Jin Shui, Xue-Mei Ye, He-Qing Yi, Cen Lou
Journal of International Medical Research.2021; 49(5): 030006052110126. CrossRef
Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine
Antonio Matrone, Alessio Faranda, Francesco Latrofa, Carla Gambale, Delio Stefani Donati, Eleonora Molinaro, Laura Agate, David Viola, Paolo Piaggi, Liborio Torregrossa, Fulvio Basolo, Rossella Elisei
The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): e2845. CrossRef

Thyroid
Procalcitonin as Marker of Recurrent Medullary Thyroid Carcinoma: A Systematic Review and Meta-Analysis: Pierpaolo Trimboli, Luca Giovanella; Endocrinol Metab. 2018;33(2):204-210. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.204

4,599 View
63 Download
11 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Calcitonin measurement is pivotal in the management of medullary thyroid carcinoma (MTC), but several pitfalls can affect its reliability. Other potential markers have been proposed, and procalcitonin (ProCT) has been reported as promising. The present study was undertaken to summarize the published data and provide more robust estimates on the reliability of ProCT as marker in the management of patients with MTC.

Methods

The systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The sources comprised studies published through May 2018. Original articles that reported series of MTC patients undergone ProCT during postoperative follow-up were searched. A random-effects model was used for statistical pooling of the data. The I² index was used to quantify the consistency among the studies. The Egger test evaluated the possible presence of significant publication bias. Quality assessment of the studies was performed according to Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).

Results

According to inclusion and exclusion criteria five papers, reporting 296 MTC patients undergone ProCT evaluation, were finally selected. The number of MTC with recurrence was 140. The pooled sensitivity of ProCT in detecting recurrence was 96% (95% confidence interval [CI], 92% to 99%), with neither heterogeneity (I²=0%) nor publication bias (Egger test, 3.16; P=0.99). The pooled specificity was 96% (95% CI, 87% to 100%) with mild heterogeneity (I²=66.6%), while Egger test was not calculable.

Conclusion

The present meta-analysis provides evidence that ProCT is reliable to manage MTC patients during their postoperative follow-up.

Citations

Citations to this article as recorded by

A Case of Insulinoma with Hyperprocalcitoninemia and Hypercalcitoninemia Showing Coexpression of Insulin and Calcitonin in Its Tumor Cells
Tomoko Kaketaka, Ikuo Mineo, Yu Kimura, Naohiko Ito, Yukiyoshi Okauchi, Hiromi Tamura, Shiro Adachi, Hiromi Iwahashi
Internal Medicine.2024;[Epub] CrossRef
[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
Luka Lezaic, Paola Anna Erba, Clemens Decristoforo, Katja Zaletel, Renata Mikolajczak, Helmut Maecke, Theodosia Maina, Mark Konijnenberg, Petra Kolenc, Malgorzata Trofimiuk-Müldner, Elwira Przybylik-Mazurek, Irene Virgolini, Marion de Jong, Alide C Fröber
European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(3): 892. CrossRef
Diagnostic tests for medullary thyroid carcinoma: an umbrella review
Pierpaolo Trimboli, Caterina Mian, Arnoldo Piccardo, Giorgio Treglia
Endocrine.2023; 81(2): 183. CrossRef
Advances in Diagnostics and Therapy of Medullary Thyroid Carcinoma (MTC)– A Mini-Review
Michał Miciak, Krzysztof Jurkiewicz
Clinical Cancer Investigation Journal.2023; 12(5): 1. CrossRef
Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19
Aparajita Sen, Arti Nigam, Meenakshi Vachher
International Journal of Peptide Research and Therapeutics.2022;[Epub] CrossRef
A pregnancy-specific reference interval for procalcitonin
Samuel Dockree, Jennifer Brook, Tim James, Brian Shine, Manu Vatish
Clinica Chimica Acta.2021; 513: 13. CrossRef
Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma
Luca Giovanella, Martina Fontana, Franco Keller, Frederik A. Verburg, Luca Ceriani
Clinical Chemistry and Laboratory Medicine (CCLM).2021; 59(4): 743. CrossRef
Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence
Qiaodan Zhu, Dong Xu
BMC Cancer.2021;[Epub] CrossRef
Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroid carcinoma in children and adolescents
Felix Eckelt, Roland Pfaeffle, Wieland Kiess, Juergen Kratzsch
Journal of Pediatric Endocrinology and Metabolism.2021; 34(12): 1491. CrossRef
Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis
Marisa A. Bartz-Kurycki, Omowunmi E. Oluwo, Lilah F. Morris-Wiseman
Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110496. CrossRef
Diagnostic Challenges of Medullary Thyroid Carcinoma
Robert D. Leimbach, Thanh D. Hoang, Mohamed K.M. Shakir
Oncology.2021; 99(7): 422. CrossRef
The Diagnostic and Antibiotic Reference Values of Procalcitonin for Intracranial Infection After Craniotomy
Lei Zhu, Lun Dong, Yuping Li, Guangyu Lu, Hengzhu Zhang, Xingdong Wang, Xiaoguang Liu, Zhenfei Teng, Boming Xia, Peng Zhang
World Neurosurgery.2019; 126: e1. CrossRef
Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
Endocrinology and Metabolism.2018; 33(2): 195. CrossRef

Thyroid
The Significance of Having an Excellent Patient's Comfort with Thyroid Core Needle Biopsy: Pierpaolo Trimboli, Luca Giovanella; Endocrinol Metab. 2018;33(1):53-54. Published online March 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.1.53

2,814 View
41 Download
2 Web of Science
2 Crossref

PDF PubReader ePub

Citations

Citations to this article as recorded by

A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
Faridul Haq, Andrey Bychkov, Chan Kwon Jung
Endocrine Pathology.2022; 33(4): 472. CrossRef
Does Radiofrequency Ablation Induce Neoplastic Changes in Benign Thyroid Nodules: A Preliminary Study
Su Min Ha, Jun Young Shin, Jung Hwan Baek, Dong Eun Song, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee
Endocrinology and Metabolism.2019; 34(2): 169. CrossRef

Author index